Topic: management changes
Bristol-Myers Squibb is locked in some pretty big marketing battles—but it’ll have to soldier on without its commercial leader.
Teva’s cost-cutting drive hasn’t been popular with workers or its home country of Israel. Analysts, on the other hand, like what they’ve seen.
Just as rebel investors are calling for a C-suite shakeup at Allergan, activist Carl Icahn has reportedly jumped in.
Embattled Celgene already bid goodbye to its COO and business development guru, and now it's moving up its executive ranks to make more changes.
Celgene's business development chief George Golumbeski left the company in April as Celgene struggles to recover from months of setbacks.
Novartis rejigged its exec team to further big ambitions for digital tech, tighten up compliance and replace its head of operations.
Gilead's executive v.p. of worldwide commercial operations is unexpectedly retiring, at a time when the company is facing challenges across its infectious-disease and oncology portfolios.
Monday, Axovant said COO Marion McCourt would be exit “to pursue another opportunity.” Turns out, that opportunity's at Regeneron.
Celgene Chairman Bob Hugin, an influential figure in biotech, will bid goodbye to that company next week. Where might he go next?
GlaxoSmithKline CEO Emma Walmsley has replaced 40% of the company’s top management as she aims to reposition the struggling pharma giant.